In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Caribou Biosciences, Inc.

https://cariboubio.com/

Latest From Caribou Biosciences, Inc.

Unpartnered Assets To Watch In 2024

Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months. 

Growth Commercial

Sana Lifted By Allo-CAR-T Data, Moves Ahead Into Autoimmune Disease

Sana claims to has cracked one of allo-CAR-Ts biggest challenges, blocking NK cells from destroying the therapies, and for now, investors are impressed.

Clinical Trials Companies

AbbVie Looks To Umoja To Partner On In Vivo CAR-Ts

Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.

Deals ImmunoOncology

Women In Advanced Therapies: How Diverse Is The Sector Really?

Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?

Diversity & Inclusion Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register